Search

Your search keyword '"Hartrampf, Philipp E."' showing total 252 results
Start Over Author "Hartrampf, Philipp E."
252 results on '"Hartrampf, Philipp E."'

36. Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T

Author

Hartrampf, Philipp E., primary, Hüttmann, Thomas, additional, Seitz, Anna Katharina, additional, Kübler, Hubert, additional, Serfling, Sebastian E., additional, Higuchi, Takahiro, additional, Schlötelburg, Wiebke, additional, Michalski, Kerstin, additional, Gafita, Andrei, additional, Rowe, Steven P., additional, Pomper, Martin G., additional, Buck, Andreas K., additional, and Werner, Rudolf A., additional

Published
2024
Full Text
View/download PDF

39. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

Author

Dreher, Niklas, primary, Hahner, Stefanie, additional, Fuß, Carmina T., additional, Schlötelburg, Wiebke, additional, Hartrampf, Philipp E., additional, Serfling, Sebastian E., additional, Schirbel, Andreas, additional, Samnick, Samuel, additional, Higuchi, Takahiro, additional, Weich, Alexander, additional, Lapa, Constantin, additional, Rosenwald, Andreas, additional, Buck, Andreas K., additional, Kircher, Stefan, additional, and Werner, Rudolf A., additional

Published
2023
Full Text
View/download PDF

41. Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG

Author

Kosmala, Aleksander, primary, Duell, Johannes, additional, Schneid, Simone, additional, Serfling, Sebastian E., additional, Higuchi, Takahiro, additional, Weich, Alexander, additional, Lapa, Constantin, additional, Hartrampf, Philipp E., additional, Raderer, Markus, additional, Einsele, Hermann, additional, Buck, Andreas K., additional, Topp, Max S., additional, Schlötelburg, Wiebke, additional, and Werner, Rudolf A., additional

Published
2023
Full Text
View/download PDF

43. Long-Term Nephrotoxicity of177Lu-PSMA Radioligand Therapy

Author

Steinhelfer, Lisa, primary, Lunger, Lukas, additional, Cala, Lisena, additional, Pfob, Christian H., additional, Lapa, Constantin, additional, Hartrampf, Philipp E., additional, Buck, Andreas K., additional, Schäfer, Hannah, additional, Schmaderer, Christoph, additional, Tauber, Robert, additional, Brosch-Lenz, Julia, additional, Haller, Bernhard, additional, Meissner, Valentin H., additional, Knorr, Karina, additional, Weber, Wolfgang A., additional, and Eiber, Matthias, additional

Published
2023
Full Text
View/download PDF

44. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma

Author

Duell, Johannes, primary, Buck, Andreas K., additional, Hartrampf, Philipp E., additional, Schlötelburg, Wiebke, additional, Schneid, Simone, additional, Weich, Alexander, additional, Dreher, Niklas, additional, Lapa, Constantin, additional, Kircher, Malte, additional, Higuchi, Takahiro, additional, Samnick, Samuel, additional, Serfling, Sebastian E., additional, Raderer, Markus, additional, Rasche, Leo, additional, Einsele, Hermann, additional, Topp, Max S., additional, Kosmala, Aleksander, additional, and Werner, Rudolf A., additional

Published
2023
Full Text
View/download PDF

45. Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer.

Author

Schumann, Sarah, Scherthan, Harry, Hartrampf, Philipp E., Göring, Lukas, Buck, Andreas K., Port, Matthias, Lassmann, Michael, and Eberlein, Uta

Subjects
DNA repair, THYROID cancer, MONONUCLEAR leukocytes, CANCER patients, DOUBLE-strand DNA breaks, IRRADIATION, THYROGLOBULIN
Abstract

This work reports on a model that describes patient-specific absorbed dose-dependent DNA damage response in peripheral blood mononuclear cells of thyroid cancer patients during radioiodine therapy and compares the results with the ex vivo DNA damage response in these patients. Blood samples of 18 patients (nine time points up to 168 h post-administration) were analyzed for radiation-induced γ-H2AX + 53BP1 DNA double-strand break foci (RIF). A linear one-compartment model described the absorbed dose-dependent time course of RIF (Parameters: c characterizes DSB damage induction; k1 and k2 are rate constants describing fast and slow repair). The rate constants were compared to ex vivo repair rates. A total of 14 patient datasets could be analyzed; c ranged from 0.012 to 0.109 mGy−1, k2 from 0 to 0.04 h−1. On average, 96% of the damage is repaired quickly with k1 (range: 0.19–3.03 h−1). Two patient subgroups were distinguished by k1-values (n = 6, k1 > 1.1 h−1; n = 8, k1 < 0.6 h−1). A weak correlation with patient age was observed. While induction of RIF was similar among ex vivo and in vivo, the respective repair rates failed to correlate. The lack of correlation between in vivo and ex vivo repair rates and the applicability of the model to other therapies will be addressed in further studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology.

Author

Dreher, Niklas, Hahner, Stefanie, Fuß, Carmina T., Schlötelburg, Wiebke, Hartrampf, Philipp E., Serfling, Sebastian E., Schirbel, Andreas, Samnick, Samuel, Higuchi, Takahiro, Weich, Alexander, Lapa, Constantin, Rosenwald, Andreas, Buck, Andreas K., Kircher, Stefan, and Werner, Rudolf A.

Subjects
POSITRON emission tomography, IMAGE analysis, SMALL cell lung cancer
Abstract

Background: C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in various solid cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to characterize the in-vivo CXCR4 expression in patients affected with solid tumors, along with a comparison to ex-vivo findings. Methods: A total 142 patients with 23 different histologically proven solid tumors were imaged with CXCR4-directed PET/CT using [68 Ga]Ga-pentixafor (total number of scans, 152). A semi-quantitative analysis of the CXCR4-positive tumor burden including maximum standardized uptake values (SUVmax) and target-to-background ratios (TBR) using blood pool was conducted. In addition, we performed histopathological staining to determine the immuno-reactive score (IRS) from patients' tumor tissue and investigated possible correlations with SUVmax (by providing Spearman's rho ρ). Based on imaging, we also assessed the eligibility for CXCR4-targeted radioligand therapy or non-radioactive CXCR4 inhibitory treatment (defined as more than five CXCR4-avid target lesions [TL] with SUVmax above 10). Results: One hundred three of 152 (67.8%) scans showed discernible uptake above blood pool (TBR > 1) in 462 lesions (52 primary tumors and 410 metastases). Median TBR was 4.4 (1.05–24.98), thereby indicating high image contrast. The highest SUVmax was observed in ovarian cancer, followed by small cell lung cancer, desmoplastic small round cell tumor, and adrenocortical carcinoma. When comparing radiotracer accumulation between primary tumors and metastases for the entire cohort, comparable SUVmax was recorded (P > 0.999), except for pulmonal findings (P = 0.013), indicative for uniform CXCR4 expression among TL. For higher IRS, a weak, but statistically significant correlation with increased SUVmax was observed (ρ = 0.328; P = 0.018). In 42/103 (40.8%) scans, more than five TL were recorded, with 12/42 (28.6%) exhibiting SUVmax above 10, suggesting eligibility for CXCR4-targeted treatment in this subcohort. Conclusions: In a whole-body tumor read-out, a substantial portion of prevalent solid tumors demonstrated increased and uniform [68 Ga]Ga-pentixafor uptake, along with high image contrast. We also observed a respective link between in- and ex-vivo CXCR4 expression, suggesting high specificity of the PET agent. Last, a fraction of patients with [68 Ga]Ga-pentixafor-positive tumor burden were rendered potentially suitable for CXCR4-directed therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.

Author

Kosmala, Aleksander, Duell, Johannes, Schneid, Simone, Serfling, Sebastian E., Higuchi, Takahiro, Weich, Alexander, Lapa, Constantin, Hartrampf, Philipp E., Raderer, Markus, Einsele, Hermann, Buck, Andreas K., Topp, Max S., Schlötelburg, Wiebke, and Werner, Rudolf A.

Subjects
MUCOSA-associated lymphoid tissue lymphoma, POSITRON emission tomography, CHEMOKINE receptors, CXCR4 receptors
Abstract

Background: In patients with marginal zone lymphoma (MZL), [18F]FDG PET/CT provided inconsistent diagnostic accuracy. C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in MZL and thus, may emerge as novel theranostic target. We aimed to evaluate the diagnostic performance of CXCR4-targeting [68Ga]Ga-PentixaFor when compared to [18F]FDG PET/CT in MZL. Methods: Thirty-two untreated MZL patients (nodal, n = 17; extranodal, n = 13; splenic, n = 2) received [68Ga]Ga-PentixaFor and [18F]FDG PET/CT within median 2 days. We performed a visual and quantitative analysis of the total lymphoma volume by measuring maximum/peak standardized uptake values (SUVmax/peak), and calculating target-to-background ratios (TBR, defined as lesion-based SUVpeak divided by SUVmean from blood pool). Visual comparisons for both radiotracers were carried out for all target lesions (TL), and quantitative analysis of concordant TL evident on both scans. Last, MZL subtype analyses were also conducted. Results: On a patient-based level, [68Ga]Ga-PentixaFor identified MZL manifestations in 32 (100%) subjects (vs. [18F]FDG, 25/32 [78.1%]). Of the 256 identified TL, 127/256 (49.6%) manifestations were evident only on CXCR4-directed imaging, while only 7/256 (2.7%) were identified on [18F]FDG but missed by [68Ga]Ga-PentixaFor. In the remaining 122/256 (47.7%) concordant TL, [68Ga]Ga-PentixaFor consistently provided increased metrics when compared to [18F]FDG: SUVmax, 10.3 (range, 2.53–37.2) vs. 5.72 (2.32–37.0); SUVpeak, 6.23 (1.58–25.7) vs. 3.87 (1.54–27.7); P < 0.01, respectively. Concordant TL TBR on [68Ga]Ga-PentixaFor (median, 3.85; range, 1.05–16.0) was also approximately 1.8-fold higher relative to [18F]FDG (median, 2.08; range, 0.81–28.8; P < 0.01). Those findings on image contrast, however, were driven by nodal MZL (P < 0.01), and just missed significance for extranodal MZL (P = 0.06). Conclusions: In newly diagnosed MZL patients, [68Ga]Ga-PentixaFor identified more sites of disease when compared to [18F]FDG, irrespective of MZL subtype. Quantitative PET parameters including TBR were also higher on [68Ga]Ga-PentixaFor PET/CT, suggesting improved diagnostic read-out using chemokine receptor-targeted imaging. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results